Project description:The goal of this study is to molecularly characterize regulatory variation in pancreatic progenitor cells (PPC). Here, we derived PPC from iPSCs of nine iPSCORE individuals (DeBoever et al., 2017; Panopoulos et al., 2017), and generated RNA-seq, ATAC-seq, scRNA-seq, and snATAC-seq. We strive to understand the role of functional genetic variation during fetal pancreatic development that later give rise to adult pancreatic diseases.
Project description:The goal of this study is to understand the effects of genetic variation on gene expression in fetal-like pancreatic progenitor cells. We generated bulk RNA-seq from 107 iPSC-derived pancreatic progenitor cells (iPSC-PPC) from iPSC lines derived from 106 individuals from the iPSCORE resource. We then conducted genome-wide expression quantitative trait loci analyses to identify genetic variants associated with gene expression and isoform usage.
Project description:Ptf1a was identified as the essential transcription factor which controls pancreatic exocrine enzyme expression. With lineage tracing eperiments Ptf1a was recognized as an important pancreatic progenitor transcription factor and Ptf1a null mice do not develop a pancreas. We used gene expression arrays to determine the global differeences in expression levels when pancreatic progenitor cells are expanding in Ptf1a heterozygote versus null mutants at E10.5. Ptf1a E10.5 dorsal pancreas total RNA from pools of 3 embryos was twice linear amplified and hybridized to Affymetrix GeneChip Mouse Genome 430 2.0 in triplicate for the Ptf1a KO and in duplicate for the Ptf1a heterozygote
Project description:We performed a microarray experiment to analyze the transcriptional profile of CHARGE patient iPSC-derived neural stem/progenitor cells to identify CHD7 target genes.
Project description:To investigate the disease-associated differences in gene expression pattern during neuro developmental stage between the discordant twins, we performed RNA sequecing-based transcriptome analyses of iPSC-derived neural cells.
Project description:Ptf1a was identified as the essential transcription factor which controls pancreatic exocrine enzyme expression. With lineage tracing eperiments Ptf1a was recognized as an important pancreatic progenitor transcription factor and Ptf1a null mice do not develop a pancreas. We used gene expression arrays to determine the global differeences in expression levels when pancreatic progenitor cells are expanding in Ptf1a heterozygote versus null mutants at E10.5.
Project description:A small molecule, AT7867, is a proliferation-promoting factor of human iPS cell-derived pancreatic progenitor cells; yet how it promotes cell proliferation is not known. AT7867 induces proliferation of pancreatic progenitor cells, but not that of definitive endoderm cells or primitive gut tube cells suggesting a cell type-specific effect. Our aim is to perform RNA-seq of cells obtained during a three stage differentiation of hiPS cells to the endodermal cell lineage in addition to pancreatic progenitor cells treated with AT7867, and analyze signaling pathways altered by the compound treatment.
Project description:Induced pluripotent stem cells (iPSC) offer a promising platform to model early embryonic developmental processes, to create disease models and proof-of-concept experiments for regenerative medicine. However, generation of iPSC derived hemato-endothelial and hematopoietic progenitor cells for these applications is challenging due to variable and limited cell numbers, which necessitates enormous up-scaling or development of demanding protocols. Here, we unravel the function of key transcriptional regulators SCL, LMO2, GATA2, ETV2 (SLGE) on early hemato-endothelial specification and establish a fully inducible and stepwise hemato-endothelial forward programming system, based on SLGE regulated overexpression. Regulated induction of SLGE in stable SLGE-iPSC lines drives very efficient generation of large numbers of hemato-endothelial progenitor cells (HEP) (CD144+/CD73-), which generate hematopoietic progenitor cells (CD45+/CD34+/CD38-/CD45RA-/CD90+/CD49f+) through a gradual process of endothelial-to-hematopoietic transition (EHT).